The roles of the Pseudomonas aeruginosa Prc/AlgO protease - Resubmission - 1
铜绿假单胞菌 Prc/AlgO 蛋白酶的作用 - 重新提交 - 1
基本信息
- 批准号:10312116
- 负责人:
- 金额:$ 21.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-12-07 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:Acute PneumoniaAddressAdoptedAffectAlginatesAnabolismAntibiotic ResistanceAntibioticsBacteriaC-terminalCatalytic DomainCell WallCellsCystic FibrosisDangerousnessDataDevelopmentDiseaseDisease OutbreaksDrug TargetingEnzymesEscherichia coliFundingFutureGoalsHealthHost DefenseHumanHydrolaseImmune systemIndividualInfectionLifeLinkMetabolismModelingMulti-Drug ResistanceN-Acetylmuramoyl-L-alanine AmidaseN-terminalNamesNosocomial InfectionsPatientsPeptide HydrolasesPeptidoglycanPhenotypePlayPolysaccharidesProcessProductionPrognosisProteinsPseudomonas aeruginosaRegulationRegulonResearchRoleSigma FactorTestingTherapeutic InterventionVirulenceWorkWound Infectionacute infectioncell envelopecell growthchronic infectioncleavage factorcostcrosslinkcystic fibrosis patientsextracellulargenetic regulatory proteinhuman pathogeninsightlung colonizationmucoidnew therapeutic targetnovelnovel therapeutic interventionpathogenpathogenic bacteriaperiplasmresistant straintargeted treatmenttherapeutic target
项目摘要
PROJECT SUMMARY
The bacterial pathogen Pseudomonas aeruginosa causes life-threatening human illnesses, including acute
pneumonia, long-term lung colonization in cystic fibrosis patients, and severe wound infections. Most infections
are associated with compromised host defenses and this, together with the common environmental occurrence
of P. aeruginosa, makes it a leading cause of hospital-acquired infections. Treatment of P. aeruginosa disease
is often challenging, in part because of its intrinsic resistance to antibiotics as well as occasional outbreaks of
multi-drug-resistant strains. Therefore, there is an urgent need to characterize new targets for therapeutic
attack. The P. aeruginosa cell envelope contains a C-terminal processing protease (CTP) named CtpA, which
is essential for acute infection. CtpA has adopted a similar role to that of the only CTP found in Escherichia
coli, Prc, even though CtpA and Prc are quite different from each other. Both CtpA in P. aeruginosa, and Prc in
E. coli, degrade enzymes that remodel the bacterial cell wall. This is intriguing because whereas many bacteria
like E. coli have only one CTP, P. aeruginosa has two, and the second one is named Prc because it is very
similar to E. coli Prc. This raises the new question for this exploratory/developmental proposal: if CtpA
achieves the role played by Prc in E. coli, then what does Prc do in Pa? Prc has been proposed to cleave the
negative regulatory protein MucA, triggering extracellular polysaccharide production and a phenotype
associated with a poor prognosis in cystic fibrosis patients. However, neither MucA or any other P. aeruginosa
protein has been demonstrated to be a Prc substrate. From our preliminary data, we are proposing an exciting
new model for the differential control of at least one PG cross-link hydrolase by both Prc and CtpA. Together
with our other observations suggesting that Prc affects the cell wall, this supports our central hypothesis, which
is that Prc cleaves important proteins involved in cell wall metabolism, and that this might have an indirect
impact on the cleavage of the anti-sigma factor MucA. To test this hypothesis, we will: (1) Determine if Prc and
CtpA play different roles in degrading common substrates and (2) Establish how Prc affects alginate regulation
and the mucoid conversion phenotype. This work will impact our understanding of fundamental, conserved
processes important to almost all bacteria. It will also provide the first clear insight into exactly what Prc does in
Pa, and the mechanism(s) by which it affects alginate biosynthesis, mucoid conversion, and cell wall features
that impact human health. Understanding these mechanisms might ultimately help the development of new
therapeutic strategies against this widespread, dangerous and very costly human pathogen.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW J. DARWIN其他文献
ANDREW J. DARWIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW J. DARWIN', 18)}}的其他基金
C-terminal proteolysis in the Pseudomonas aeruginosa cell envelope
铜绿假单胞菌细胞包膜中的 C 末端蛋白水解
- 批准号:
10319533 - 财政年份:2018
- 资助金额:
$ 21.19万 - 项目类别:
The Pseudomonas aeruginosa protease CtpA and type 3 secretion
铜绿假单胞菌蛋白酶CtpA和3型分泌
- 批准号:
8995635 - 财政年份:2015
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
6717703 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
8215878 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
8241198 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
8418767 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersina enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
8695130 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersina enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
9258378 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
7650987 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
7186637 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 21.19万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 21.19万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 21.19万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 21.19万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 21.19万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 21.19万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 21.19万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 21.19万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 21.19万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 21.19万 - 项目类别:
Research Grant














{{item.name}}会员




